论文部分内容阅读
目的:探讨射频消融联合Hassab术治疗肝癌合并门静脉高压症的有效性和安全性。方法:回顾性分析2013年6月至2015年6月北京地坛医院普外科收治的原发性肝癌合并门静脉高压症行手术治疗的患者临床资料。根据手术方式将患者分为射频消融联合Hassab术组和肝切除联合Hassab术组。比较两组患者的一般资料、手术时间、术中出血量、术中是否输血、术后住院时间、术后并发症等指标以及两组患者的1、3、5年累积生存率和无复发生存率。结果:共53例患者纳入研究。射频消融联合Hassab术组30例，其中男性28例，女性2例，平均年龄46.3(27.0～64.0)岁；肝切除联合Hassab术组23例，其中男性20例，女性3例，平均年龄44.7(33.0～59.0)岁。两组患者的年龄、性别、肿瘤最大径、术前实验室检查(包括血常规、肝功能、肿瘤标记物)以及Child-Pugh分级等一般资料差异无统计学意义(均n P>0.05)。射频消融联合Hassab术组术中出血量少于肝切除联合Hassab术组[(401.67±183.12)ml比(552.17±333.88)ml]，差异有统计学意义(n P0.05)。肝切除联合Hassab术组的术后严重并发症(Clavein-Dindo分级≥IIIb)发生率为47.8%(11/23)，高于射频消融联合Hassab术组的20.0%(6/30)，差异有统计学意义(n P0.05)。射频消融联合Hassab术组患者术后1、3、5年的无复发生存率分别为79.2%、38.8%和21.6%，肝切除联合Hassab术组患者术后1、3、5年的无复发生存率分别为76.4%、41.7%和27.8%，两组差异均无统计学意义(均n P>0.05)。n 结论:射频消融联合Hassab术治疗肝癌合并门静脉高压症安全有效。“,”Objective:To study the efficacy and safety of Hassab operation combined with either radiofrequency ablation(RFA) or liver resection in treatment of liver cancer associated with portal hypertension.Methods:A retrospective analysis was conducted on the clinical data of patients with primary liver cancer associated with portal hypertension operated at the Department of General Surgery of Beijing Ditan Hospital from June 2013 to June 2015. These patients were divided into the RFA combined with Hassab operation group and the liver resection combined with Hassab operation group according to the surgical procedures. The general patient information, operation time, intraoperative blood loss, intraoperative blood transfusion, postoperative hospital stay, postoperative complications and the 1-, 3-, and 5-years cumulative survival rates and recurrence-free survival rates were compared.Results:Of 53 patients who were included in the study, 30 patients were in the RFA combined with Hassab operation group (including 28 males and 2 females, average age 46.3 (27.0~64.0) years, and 23 patients in the liver resection combined with Hassab operation group (including 20 males and 3 females), average age 44.7(33.0~59.0) years. There were no significant differences in the general patient information including age, gender, maximum tumor diameter, preoperative laboratory tests (including blood routine, liver function, tumor markers), and Child-Pugh classification between the two groups (all n P>0.05). Intraoperative blood loss in the RFA combined with Hassab operation group was significantly less than those in the liver resection combined with Hassab operation group [(401.67±183.12) ml vs (552.17±333.88) ml,n P0.05). The incidence of severe postoperative complications (Clavein-Dindo grade ≥ IIIb) in the liver resection combined with Hassab operation group was 47.8% (11/23), which was significantly higher than the 20.0% (6/30) in the RFA combined with Hassab operation group (n P0.05). The recurrence-free survival rates of patients in the RFA combined with Hassab operation group at 1-, 3-, and 5-years after surgery were 79.2%, 38.8%, and 21.6%, respectively. The corresponding recurrence-free survival rates of patients in the liver resection combined with Hassab operation group were 76.4%, 41.7%, and 27.8%, respectively, and there was no significant difference between the two groups (n P>0.05).n Conclusion:RFA combined with Hassab operation was safe and efficacious to treat primary liver cancer associated with portal hypertension.